Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026Unusual Whales·Jul 27 at 06:02 AMHROW+0.16%HROWM0.00%
Harrow updates financial calendar with upcoming quarterly results release and investor callPUBT·Jul 27 at 06:02 AMHROWL0.00%HROW+0.16%
The Age of Compliance and Desperation: Inside the Mid-Cap CrucibleGlobal Report·Jul 25 at 04:13 AMNCLH-8.70%RCON-2.53%
Niche Players Accelerate 2026 Capital Deployment: Equinox Revenue Doubles as iPower Pivots to AIGlobal Report·Jul 24 at 04:13 AMEQX+3.91%CGNX+7.32%
From Nuclear Tech to AI Liquid Cooling: Unpacking Micro-Cap OverhaulsGlobal Report·Jul 22 at 04:18 AMASPI+11.44%NPT+3.07%
Can New Retina Data Deepen Harrow’s (HROW) Moat In Ophthalmology Or Just Refine Its Story?Simplywall·Jul 20 at 08:08 PMHROW+0.16%HROWM0.00%
Harrow says QUELL trial of IHEEZO posts topline data in Q4 2026PUBT·Jul 20 at 06:07 AMHROW+0.16%HROWM0.00%
A Cross-Section of Market Divergence: From Macro Hedges to AI Reality ChecksGlobal Report·Jul 18 at 04:12 AMQMCO+5.93%NTGR+0.64%
How Investors May Respond To Harrow (HROW) Taking Over BYOOVIZ US Commercialization And Ophthalmic BiosimilarsSimplywall·Jul 10 at 03:03 AMHROW+0.16%HROWM0.00%
Harrow (NASDAQ:HROW) Trading Down 4.8% - What's Next?Market Beat·Jul 9 at 01:40 PMHROW+0.16%HROWM0.00%
8 Health Care Stocks With Whale Alerts In Today’s Sessionbenzinga_article·Jul 6 at 12:35 PMHROW+0.16%MRK-0.30%
Harrow (HROW) Could Be 38% Undervalued Following BYOOVIZ LaunchSimplywall·Jul 3 at 10:57 AMHROWM0.00%HROW+0.16%
Analyst Reaffirms Buy on Harrow Health, Citing Expanding Ophthalmic Franchise and Long-Term Growth PipelineTip Ranks·Jul 1 at 08:45 AMHROWM0.00%HROWL0.00%
Harrow holds annual shareholder meeting, elects four directorsPUBT·Jun 22 at 06:31 AMHROW+0.16%HROWL0.00%
